Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$11.50 USD
-1.20 (-9.45%)
Updated May 17, 2024 04:00 PM ET
After-Market: $11.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CADL 11.50 -1.20(-9.45%)
Will CADL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CADL
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
Other News for CADL
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
Candel Therapeutics Reports First Quarter 2024 Financial ResultsĀ and Recent Corporate Highlights
Candel Therapeutics reports Q1 EPS (28c) vs (30c) last year